Ravi Kilaru, MD
Cardiovascular Disease · Bremerton, WANPI 1508823097
Payments from drug & device makers
Across 43 payments — averaging $122.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Atricure, Inc.$1K
- Boston Scientific$1K
- Biosense Webster, Inc.$1K
- Philips North America LLC$122
- Inari Medical, Inc.$110
- plus $154 from 3 others
What the payments were for
- Travel & lodging$3,00557%
- Food & beverage$2,19042%
- Education$701%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 5 | $1,463 |
| Atricure, Inc. | 9 | $1,204 |
| Boston Scientific | 9 | $1,162 |
| Biosense Webster, Inc. | 9 | $1,051 |
| Philips North America LLC | 1 | $122 |
| Inari Medical, Inc. | 5 | $110 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $65 |
| Abbott | 1 | $57 |
| E.r. Squibb & Sons, L.L.C. | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,265 in reported general payments places this provider in the 75th percentile of 370 cardiovascular disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 254 | $329,640 |
| XareltoRivaroxaban | 99 | $146,471 |
| Metoprolol Succinate | 262 | $5,117 |
| Flecainide Acetate | 125 | $4,183 |
| PradaxaDabigatran Etexilate Mesylate | 12 | $3,596 |
| Amiodarone Hcl | 47 | $3,332 |
| Mexiletine Hcl | 17 | $2,354 |
| SotalolSotalol Hcl | 49 | $1,253 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 28 | $801 |
| Dofetilide | 18 | $800 |
| Pantoprazole Sodium | 55 | $289 |
| Carvedilol | 30 | $238 |
| Lisinopril | 24 | $191 |
| Losartan Potassium | 12 | $155 |
| Amlodipine Besylate | 19 | $127 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Bremerton
- Vinay MalhotraTacoma$5M
- Francis KimSeattle$1.7M
- Ahmad SlimTacoma$1.1M
- Kelley BranchSeattle$715K
- Robert BersinBellevue$677K
- Mariko HarperSeattle$453K
- David OwensSeattle$325K
- John PetersenSeattle$309K
- Bryan FuhsSpokane$268K
- Eugene YangBellevue$266K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.